91 papers and 72 clinical trials exploring esketamine as a treatment for depressive disorders.
Blossom tracks 91 papers and 72 clinical trials examining esketamine as a treatment for depressive disorders. Esketamine acts primarily as a nmda receptor antagonist. The papers and trials below are sorted by recency, and reported adverse events and dosing protocols are summarised in the linked overviews.
Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.
Full Esketamine profileDepression is the flagship indication for psychedelic and rapid-acting psychiatry, and the place where the field has gone furthest: an approved drug (esketamine), the first Phase 3 win for a classic psychedelic, and several striking trials of psilocybin for major depression. But it is also where the honest caveats bite hardest. The most rigorous recent analyses suggest much of psilocybin’s apparent edge comes from patients knowing they got the drug, and a head-to-head against a standard antidepressant was not significant on its main measure. This is the umbrella page for the depression family; the resistant, general and bipolar forms each have their own.
Full Depressive Disorders profileEsketamine safety reports for Depressive Disorders most often include dizziness, headache, nausea, paresthesia among the source-backed named adverse events currently normalized in Blossom.
Esketamine clinical studies for Depressive Disorders include 24 structured dose rows across 20 linked trials. Common source-reported dose patterns include 84 mg, 0.2 mg/kg, 56 mg. Interpret these as descriptive trial protocols, not treatment recommendations.